Logo image of STIM

NEURONETICS INC (STIM) Stock Fundamental Analysis

NASDAQ:STIM - Nasdaq - US64131A1051 - Common Stock - Currency: USD

3.915  +0.06 (+1.69%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to STIM. STIM was compared to 188 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of STIM have multiple concerns. STIM is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

STIM had negative earnings in the past year.
In the past year STIM has reported a negative cash flow from operations.
STIM had negative earnings in each of the past 5 years.
In the past 5 years STIM always reported negative operating cash flow.
STIM Yearly Net Income VS EBIT VS OCF VS FCFSTIM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M

1.2 Ratios

STIM has a Return On Assets (-34.16%) which is in line with its industry peers.
With a Return On Equity value of -136.83%, STIM is not doing good in the industry: 67.02% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -34.16%
ROE -136.83%
ROIC N/A
ROA(3y)-29.62%
ROA(5y)-29.17%
ROE(3y)-103.71%
ROE(5y)-91.08%
ROIC(3y)N/A
ROIC(5y)N/A
STIM Yearly ROA, ROE, ROICSTIM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100 200

1.3 Margins

STIM has a better Gross Margin (63.51%) than 65.43% of its industry peers.
STIM's Gross Margin has been stable in the last couple of years.
STIM does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 63.51%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.88%
GM growth 5Y-0.84%
STIM Yearly Profit, Operating, Gross MarginsSTIM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 60 80

More info and screens

3

2. Health

2.1 Basic Checks

STIM does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, STIM has more shares outstanding
STIM has more shares outstanding than it did 5 years ago.
STIM has a better debt/assets ratio than last year.
STIM Yearly Shares OutstandingSTIM Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
STIM Yearly Total Debt VS Total AssetsSTIM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M

2.2 Solvency

Based on the Altman-Z score of -2.71, we must say that STIM is in the distress zone and has some risk of bankruptcy.
STIM has a worse Altman-Z score (-2.71) than 64.89% of its industry peers.
A Debt/Equity ratio of 1.56 is on the high side and indicates that STIM has dependencies on debt financing.
Looking at the Debt to Equity ratio, with a value of 1.56, STIM is doing worse than 81.91% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 1.56
Debt/FCF N/A
Altman-Z -2.71
ROIC/WACCN/A
WACC9.06%
STIM Yearly LT Debt VS Equity VS FCFSTIM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M 80M

2.3 Liquidity

A Current Ratio of 2.44 indicates that STIM has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 2.44, STIM is in line with its industry, outperforming 45.74% of the companies in the same industry.
STIM has a Quick Ratio of 2.28. This indicates that STIM is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of STIM (2.28) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 2.44
Quick Ratio 2.28
STIM Yearly Current Assets VS Current LiabilitesSTIM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

5

3. Growth

3.1 Past

STIM shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -36.46%.
Looking at the last year, STIM shows a very strong growth in Revenue. The Revenue has grown by 22.16%.
The Revenue has been growing slightly by 3.63% on average over the past years.
EPS 1Y (TTM)-36.46%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%22.22%
Revenue 1Y (TTM)22.16%
Revenue growth 3Y10.63%
Revenue growth 5Y3.63%
Sales Q2Q%83.59%

3.2 Future

The Earnings Per Share is expected to grow by 18.70% on average over the next years. This is quite good.
STIM is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 29.63% yearly.
EPS Next Y73.57%
EPS Next 2Y36.6%
EPS Next 3Y24.73%
EPS Next 5Y18.7%
Revenue Next Year108.08%
Revenue Next 2Y51.77%
Revenue Next 3Y38.37%
Revenue Next 5Y29.63%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
STIM Yearly Revenue VS EstimatesSTIM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 50M 100M 150M 200M
STIM Yearly EPS VS EstimatesSTIM Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 -0.5 -1 -1.5 -2

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

STIM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for STIM. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
STIM Price Earnings VS Forward Price EarningsSTIM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 -20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
STIM Per share dataSTIM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1

4.3 Compensation for Growth

STIM's earnings are expected to grow with 24.73% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.6%
EPS Next 3Y24.73%

More info and screens

0

5. Dividend

5.1 Amount

STIM does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NEURONETICS INC

NASDAQ:STIM (5/29/2025, 12:25:05 PM)

3.915

+0.06 (+1.69%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)05-06 2025-05-06/bmo
Earnings (Next)08-11 2025-08-11/bmo
Inst Owners14.36%
Inst Owner Change100.11%
Ins Owners6.06%
Ins Owner Change8.97%
Market Cap257.69M
Analysts80
Price Target6.97 (78.03%)
Short Float %10.26%
Short Ratio3.06
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-59.38%
Min EPS beat(2)-64.71%
Max EPS beat(2)-54.06%
EPS beat(4)0
Avg EPS beat(4)-56.54%
Min EPS beat(4)-87.55%
Max EPS beat(4)-19.83%
EPS beat(8)3
Avg EPS beat(8)-16.91%
EPS beat(12)7
Avg EPS beat(12)-5.54%
EPS beat(16)8
Avg EPS beat(16)-4.76%
Revenue beat(2)2
Avg Revenue beat(2)10.08%
Min Revenue beat(2)7.85%
Max Revenue beat(2)12.31%
Revenue beat(4)2
Avg Revenue beat(4)0.4%
Min Revenue beat(4)-13.51%
Max Revenue beat(4)12.31%
Revenue beat(8)3
Avg Revenue beat(8)0.09%
Revenue beat(12)7
Avg Revenue beat(12)1.54%
Revenue beat(16)9
Avg Revenue beat(16)0.9%
PT rev (1m)0%
PT rev (3m)105%
EPS NQ rev (1m)-3.23%
EPS NQ rev (3m)55.56%
EPS NY rev (1m)-12.7%
EPS NY rev (3m)45.66%
Revenue NQ rev (1m)-0.25%
Revenue NQ rev (3m)60.23%
Revenue NY rev (1m)1.13%
Revenue NY rev (3m)60.61%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.88
P/FCF N/A
P/OCF N/A
P/B 7.27
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.31
EYN/A
EPS(NY)-0.18
Fwd EYN/A
FCF(TTM)-0.57
FCFYN/A
OCF(TTM)-0.55
OCFYN/A
SpS1.36
BVpS0.54
TBVpS-0.04
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -34.16%
ROE -136.83%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 63.51%
FCFM N/A
ROA(3y)-29.62%
ROA(5y)-29.17%
ROE(3y)-103.71%
ROE(5y)-91.08%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.88%
GM growth 5Y-0.84%
F-Score2
Asset Turnover0.63
Health
Industry RankSector Rank
Debt/Equity 1.56
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 54.04%
Cap/Sales 1.46%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.44
Quick Ratio 2.28
Altman-Z -2.71
F-Score2
WACC9.06%
ROIC/WACCN/A
Cap/Depr(3y)129%
Cap/Depr(5y)137.27%
Cap/Sales(3y)3.43%
Cap/Sales(5y)3.2%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-36.46%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%22.22%
EPS Next Y73.57%
EPS Next 2Y36.6%
EPS Next 3Y24.73%
EPS Next 5Y18.7%
Revenue 1Y (TTM)22.16%
Revenue growth 3Y10.63%
Revenue growth 5Y3.63%
Sales Q2Q%83.59%
Revenue Next Year108.08%
Revenue Next 2Y51.77%
Revenue Next 3Y38.37%
Revenue Next 5Y29.63%
EBIT growth 1Y-35.6%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year77.95%
EBIT Next 3Y32.94%
EBIT Next 5Y26.07%
FCF growth 1Y-3%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-6.53%
OCF growth 3YN/A
OCF growth 5YN/A